EXOZ

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. ("Curia"), a global leader in contract manufacturing, to initiate technology The agreement represents the next major step in advancing eXoZymes' proprietary NCT manufacturing process from successful pilot-scale validation toward commercial manufacturing. Damien Perriman, Chief Commercial Officer of eXoZymes, states, "We are advancing the work required to establish the manufacturing pathway and supply chain to support NCT's planned commercial launch.

eXoZymes NASDAQ: EXOZ outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter.

Management to host Q2 2026 update at 5PM ET / 2PM PT, today. LOS ANGELES, CA / ACCESS Newswire / August 20, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30, 2026, and provide an update on recent business developments.

Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing. Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes. The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.

Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules. NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partnership and commercialization.

LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants. The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common stock and one warrant to purchase one additional share of common stock.

LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Chief Commercial Officer, Damien Perriman was featured on the latest episode of the industry leading Grow Everything podcast to discuss the company's first spinout, NCTx, and how eXoZymes is building a repeatable commercialization model for high-value natural products. The Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder.

LOS ANGELES, CA / ACCESS Newswire / March 25, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these results will be issued prior to the call.